Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System (CV)
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
BPH and hypertension are chronic senile diseases that increase in prevalence with age. It is reported that 25% of men over 60 years old suffer from both BPH and hypertension. Though these two diseases differ in nature, there is a hypothesis advanced from recent studies that for both diseases, increase in sympathetic tone plays an important role in pathophysiology.
As a medical treatment of BPH, α-blockers are widely selected in clinical studies as a first line treatment in patients with LUTS, for its non-invasiveness and superior clinical efficacy [1, 5]. Such α-blockers increases urine flow and decreases residual urine by controlling excitement of the sympathetic nervous system distributed around smooth muscle of prostate and bladder neck. Through this, α-blockers improve conditions of clinical symptoms of patients suffering from LUTS due to BPH, and decrease need for invasive surgery related to BPH, and also have medical action to decrease morbidity rate of secondary complications of BPH such as acute retention of urine, deterioration of renal function, bladder stone and urinary tract infection.
However, in the case of patients who are on hypertension medication, when considering concomitant administration with α-blockers, adverse events such as orthostatic hypotension and dizziness due to drop in blood pressure is most concerned. In this regard, silodosin, as an alpha 1A adrenoceptor antagonist, has been proven have low occurrence of adverse events related to cardiovascular system and have little effect on blood pressure compared to other α-blockers.
Thus, in this study, we aim to see the effect on cardiovascular system(blood pressure) Thrupas® capsule is administered every day for 12 weeks in patients with LUTS suggestive of BPH.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Seoul, Corea, Repubblica di, 138-736
- Asan Medical Center
-
Seoul, Corea, Repubblica di, 137-701
- Seoul St. Mary's Hospital of the Catholic University of Korea
-
Seoul, Corea, Repubblica di, 135-720
- Gangam Severance Hospital
-
-
Gyeonggi-do
-
Anyang-si, Gyeonggi-do, Corea, Repubblica di, 431-796
- Hallym University Sacred Heart Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The number of study subjects was calculated based on safety end-point which was variable change in SBP measurement before and after the administration of Silodosin. In previous studies, the standard deviation in before and after administration of Silodosin was 12.81. Therefore, this study assumed the standard deviation in before and after administration to be 12.81.
When the significance level was 0.05, the confidence interval was 1.41 and standard deviation of SBP measurement before and after the administration of Silodocsin was 12.81, the standard sample size will be 318 people and target number of study subject will be 400 as the expected drop rate is 20%.
Descrizione
Inclusion Criteria:
Patients who have been diagnosed with BPH by digital rectal exam or ultrasonographic findings and meet the following criteria.
- Male, 50 years or older
- Patients with a total I-PSS score ≥ 8
- Patients with a QoL score ≥ 3
- Patients who voluntarily decided to participate and have filled out consent form
Exclusion Criteria:
- Patients with an allergy to α-blockers
- Patients with history of severe arrhythmia, cardiac failure, cardiac infarction, unstable angina, cerebral infarction within 6 months
- Patients with severe hepatic disorders (hepatic insufficiency, cirrhosis, jaundice, hepatoma)
- Patients with renal dysfunction
- Has PSA value ≥ 10ng/ml or has been diagnosed with tumor by biopsy even if PSA value is lower than 10ng/ml,
- Patients with history of prostate surgery
- Patients previously administered with 5α-reductase inhibitor within 3 months
- Patients previously administered with α1-adrenoceptor antagonist within 1 month
- Patients who are taking the following drugs at the start of study or those who have to take during the 12 weeks of the study: αβ-adrenoceptor antagonist, α-adrenoceptor agonist, anticholinergic (tolterodine, oxybutynin, etc.)
- Patients with a history of intrapelvic radiation therapy or prostatic hyperthermia
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change in blood pressure (systolic, diastolic) before and after administration
Lasso di tempo: 3 months
|
3 months
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Eventi avversi
Lasso di tempo: 3 mesi
|
3 mesi
|
|
Change in IPSS total score before and after administration*
Lasso di tempo: 3 months
|
3 months
|
|
Change in QoL score before and after administration
Lasso di tempo: 3 months
|
3 months
|
|
Change in IPSS subscore before and after administration
Lasso di tempo: 3 months
|
3 months
|
|
Evaluation of BSW after administration
Lasso di tempo: 3 months
|
3 months
|
|
Change in Qmax before and after administration
Lasso di tempo: 3 months
|
3 months
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- JWP-SDS-405
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .